electroCore Announces Fourth Quarter and Full Year 2018 Financial Results
Fourth quarter 2018 prescription growth of more than 30% from third quarter 2018
Company to host conference call and webcast today,
Fourth Quarter 2018 and Recent Highlights
- Generated in excess of 5,800 gammaCore® prescriptions in the fourth quarter of 2018, an increase of more than 30% from the third quarter 2018
- Generated approximately 15,000 gammaCore® prescriptions in 2018
- Over 1,800 unique prescribing physicians through the fourth quarter of 2018, up from approximately 1,500 in the third quarter 2018
- Commercial payer coverage together with the Federal Supply Schedule increased covered lives to 53 million
“During the fourth quarter, we continued to execute on our commercial growth plan, led by our ongoing progress toward increasing covered lives through productive discussions with national and regional payers,” said
Fourth Quarter and Full Year 2018 Financial Results
For the quarter ending
Total operating expenses for fourth quarter of 2018 were
Operating loss for the fourth quarter of 2018 was
For the full year, net sales were
Full year 2018 gross profit was
Total operating expenses were
Operating loss for the full year 2018 was
Cash and cash equivalents and marketable securities at
Webcast and Conference Call Information
electroCore’s management team will host a conference call today beginning at
A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.electrocore.com.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s current indications are for the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and product development plans, its pipeline or potential markets for its technologies, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the
LifeSci Public Relations